Granted Patent B1

US 12,263,304 · App. 17/480,703 · Granted Apr 1, 2025

Inventor: Jon E Hilliard (Gastonia, NC)

A61M16/06A45D44/002A61M35/10A62B18/084A62B23/025B01D39/08B01D2239/0478B01D2239/0654

Abstract

Claims (62)

1. A face mask impregnated with medicine comprising

a mask structure, a fastening structure, and a medical coating;

wherein the face mask impregnated with medicine is configured for use with a patient;

wherein the fastening structure is configured to attach the mask structure to the patient;

wherein the medical coating is a pharmacologically active media that is configured to treat medical conditions that are caused or exacerbated by the mask structure;

wherein the face mask impregnated with medicine is configured to cover the mouth and nose on the face of the patient;

wherein the face mask impregnated with medicine is configured to filter the air that is inhaled and exhaled by the patient;

wherein the mask structure is configured to filter the air that is inhaled and exhaled by the patient;

wherein the medical coating is selected from the group consisting of: a) a pharmacologically active media with a primary chemical structure of (all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (CAS 302-79-4); and, b) a pharmacologically active media with a primary chemical structure of α-[[(1.1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol (CAS 18559-94-9).

2. A face mask impregnated with medicine comprising

a mask structure, a fastening structure, and a medical coating;

wherein the fastening structure attaches to the mask structure;

wherein the medical coating is applied to the mask structure;

wherein the mask structure comprises an inner layer, a filter layer, and an outer layer;

wherein the filter layer is sandwiched between the inner layer and the outer layer;

wherein the medical coating is configured to be applied to the face of the inner layer that is proximal to the face of the patient;

wherein the medical coating is selected from the group consisting of: a) a pharmacologically active media with a primary chemical structure of (all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (CAS 302-79-4); and, b) a pharmacologically active media with a primary chemical structure of α-[[(1.1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol (CAS 18559-94-9).

3. The face mask impregnated with medicine according to claim 2 ,

wherein the face mask impregnated with medicine is adapted for use with a patient;

wherein the face mask impregnated with medicine is configured to cover the mouth and nose on the face of the patient;

wherein the face mask impregnated with medicine is configured to filter the air that is inhaled and exhaled by the patient.

4. The face mask impregnated with medicine according to claim 3 ,

wherein the mask structure is configured to filter the air that is inhaled and exhaled by the patient;

wherein the fastening structure is configured to attach the mask structure to the patient;

wherein the medical coating is a pharmacologically active media.

5. The face mask impregnated with medicine according to claim 4 ,

wherein the mask structure is a textile based structure;

wherein the mask structure is a composite textile.

6. The face mask impregnated with medicine according to claim 5 ,

wherein the medical coating is a pharmacologically active media;

wherein the medical coating is formed as a gas permeable structure;

wherein the medical coating is configured to be selected from the group consisting of a topically applied pharmacologically active media and an inhaled pharmacologically active media.

7. The face mask impregnated with medicine according to claim 6 ,

wherein the fastening structure is a mechanical structure;

wherein the fastening structure is configured to attach to the mask structure;

wherein the fastening structure is configured to secure the mask structure to the patient;

wherein the fastening structure is an elastic structure.

8. The face mask impregnated with medicine according to claim 7 ,

wherein the inner layer is one selected from the group consisting of: a sheeting structure; a textile based structure; the composite prism structure of the mask structure that is proximal to the face of the patient; and a gas permeable structure.

9. The face mask impregnated with medicine according to claim 8 ,

wherein the inner layer is an absorbent structure;

wherein the outer layer is a sheeting structure;

wherein the outer layer is a textile based structure;

wherein the outer layer is the layer of the composite prism structure of the mask structure that is distal from the face of the patient;

wherein the outer layer is a gas permeable structure;

wherein the outer layer is an absorbent structure.

10. The face mask impregnated with medicine according to claim 9 ,

wherein the filter layer is a sheeting structure;

wherein the filter layer is a textile based structure;

wherein the filter layer is a gas permeable structure;

wherein the filter layer forms a filter.

11. The face mask impregnated with medicine according to claim 10 ,

wherein the filter layer is configured to form an N95 filter.

12. The face mask impregnated with medicine according to claim 11 ,

wherein the medical coating is selected from the group consisting of: a) a pharmacologically active media with a primary chemical structure of (all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (CAS 302-79-4); and, b) a pharmacologically active media with a primary chemical structure of α-[[(1,1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol (CAS 18559-94-9).

13. The face mask impregnated with medicine according to claim 11 ,

wherein the medical coating is an (all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (CAS 302-79-4);

wherein the (all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (CAS 302-79-4) is configured to be topically applied to the patient;

wherein the (all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (CAS 302-79-4) is provided in a formulation comprising a lipid.

14. The face mask impregnated with medicine according to claim 11 ,

wherein the medical coating is a 1,3-benzenedimethanol, α1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-(CAS 18559-94-9);

wherein the 1,3-benzenedimethanol, α1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-(CAS 18559-94-9) is inhaled by the patient.

Continuity (1)

References Cited (93)